HONG KONG, June 30, 2011 /PRNewswire-Asia-FirstCall/ —
Golden Meditech Holdings Limited (“Golden Meditech,”
together with its subsidiaries collectively as the “Group,” –
801.HK; 910801.TW), a leading integrated healthcare enterprise in
China, is pleased to announce the Group’s annual results for the
year ended 31 March, 2011. During the reporting period, the
Group’s core businesses reported total turnover of HK$328,066,000,
15% growth compared to the previous year. Profit attributable
to shareholders increased substantially by 195% at HK$343,208,000
while basic earnings per share amounted to HK19.9 cents.
Mr. KAM Yuen, Chairman and Chief Executive Officer of the Group,
said the results are in-line with Group management’s expectations.
The remarkable growth in revenue is primarily driven by
stable growth in the core businesses of medical devices and
healthcare services and contribution from associates and jointly
controlled entities. At the same time, management believes
the healthcare services, as one of the Group’s key strategic
businesses, will become a key driver for future growth as it expand
its operation under the favourable policy and market
environment.
The Group’s healthcare services business currently consists of
hospital management, medical insurances administration outsourcing
business and cord blood banking operation, of which, hospital
management demonstrated most significant growth during the review
period. Revenue from hospital management (generated from the
two haematology hospitals under the Daopei brand name), reported
remarkable 55.4% increase in hospital management income to
HK$80.4million, accounted for 25% of the Group’s total turnover and
increased by 7 percentage points compared to the previous year.
On the other hand, the Group has announced two major acquisition
transactions, one in Beijing and the other in Shanghai. The
Beijing acquisition will increase the bed cou
‘/>”/>
